Achieving a MC of $2 billion or more USD would mean almost a 6 fold increase in the PPS from current levels assuming the share structure stays roughly where it is now....allowing for some dilution a 5 fold increase seems reasonable imo.

Obviously that's contingent of postive top line data as you point out BDZ. If BETonMACE fails to achieve its primary end point, notwithstanding other potential indications like CKD and Fabry's, if BETonMACE doesn't hit 30% RRR....then I could see us passing right through microcap and heading to nanocap status. 

Not trying to stir up FUD, just my take on the reality of the situtation. 

On the sunnier side of the street, if Resverlogix attained Mid Cap status....then I have little doubt that there would be significant institutional interest.  And beyond the top-line read out, assuming the results are postive, then there are the potential catalysts that come from NDAs to the FDA and EMA....

And then if Apabetalone is approved?  I don't think Large Cap status would be unrealistic at all.